Epidarex Capital
Status
ACTIVE
Global HQ
Edinburgh, United Kingdom
Countries of investment
- United Kingdom
- United States
Investment stages
- Seed
- Series A
- Series B
Industries
- Biotechnology
- MedTech
About
Epidarex Capital focuses on investing in life-science companies that emerge from under-ventured regions in the US and Europe. The firm targets medtech, therapeutics, and diagnostics companies with the potential for significant impact. Epidarex provides both capital and strategic support, helping these companies transition from early-stage R&D to commercial success. By focusing on underfunded hubs, Epidarex is able to identify hidden gems in the life sciences sector and help them scale to global markets.
Epidarex Capital focuses on investing in life-science companies that emerge from under-ventured regions in the US and Europe. The firm targets medtech, therapeutics, and diagnostics companies with the potential for significant impact. Epidarex provides both capital and strategic support, helping these companies transition from early-stage R&D to commercial success. By focusing on underfunded hubs, Epidarex is able to identify hidden gems in the life sciences sector and help them scale to global markets.
Investment Thesis
Epidarex Capital’s thesis centers on investing in under-ventured regions in the US and Europe to build world-class life science companies. It targets early-stage medtech, therapeutics, and diagnostics startups with strong scientific foundations and global commercialization potential. Epidarex aims to unlock hidden innovation ecosystems by pairing local expertise with international capital.
Manager's Experience
Led by life sciences experts with experience in biotech and healthcare venture investing, supporting early-stage companies.
Team
Sinclair Dunlop-Managing Partner
Kyparissia Sirinakis-Managing Partner
Elizabeth Roper Ph.D.-General Partner
Peter Finan Ph.D.-General Partner
Mary Canning Ph.D.-Partner
Lori Krim Gough Ph.D.-Partner
Henning Steinhagen Ph.D.-Venture Partner
Anthony Voveris-Vice President of Finance
Matthew Miessau-Principal
Victor Pong Ph.D.-Associate
Zach Hamelinck-Director
Investor Relations
Melissa Lezameta Ph.D.-Associate
Alvin Lewis-Staff Accountant
Bridget Harris-Director of Operations
Megan MacDougall-Executive Assistant
Portfolio
Harpoon Medical
XO1 Limited
T-CiRA
Oxford Cancer Biomarkers
Achilles Therapeutics
Nexstim